Trial Profile
Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capmatinib (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- Sponsors SCRI Development Innovations
- 19 Sep 2023 Status changed from active, no longer recruiting to completed.
- 06 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Sep 2023.
- 01 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.